Literature DB >> 7512481

Pharmacological aspects of calcium antagonism. Short term and long term benefits.

W G Nayler1.   

Abstract

Calcium antagonists are widely used in the management of a variety of cardiovascular disorders, including angina pectoris, myocardial infarction, atherosclerosis and hypertension. At the cellular level these drugs act primarily by limiting calcium ion (Ca++) entry through voltage-sensitive, Ca(++)-selective channels. This effect contributes to the antiatherogenic properties of calcium antagonists and is primarily responsible for their ability to reduce systolic and diastolic blood pressure, and to protect the myocardium. The cardioprotective effect of calcium antagonists is a complex phenomenon that needs to be considered in terms of the immediate consequences of Ca(++)-channel blockade and subsequent reduction in cytosolic Ca++, together with the long term benefits. These long term benefits include protection of the vasculature, an attenuation of hypertension-induced hypertrophy and improved left ventricular diastolic function. However, irrespective of whether it is the short or long term effects of calcium antagonists that are being considered, it is their ability to lower cytosolic Ca++ that is primarily responsible for their cardio- and vascular-protective effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512481     DOI: 10.2165/00003495-199300462-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

Review 1.  The cell biology of acute myocardial ischemia.

Authors:  R B Jennings; K A Reimer
Journal:  Annu Rev Med       Date:  1991       Impact factor: 13.739

2.  Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels.

Authors:  I T Mak; P Boehme; W B Weglicki
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle.

Authors:  W G Nayler; J Szeto
Journal:  Cardiovasc Res       Date:  1972-03       Impact factor: 10.787

5.  Development of cell injury in sustained acute ischemia.

Authors:  R B Jennings; C E Murry; C Steenbergen; K A Reimer
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

6.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

7.  Contractile dysfunction and ATP depletion after transient calcium overload in perfused ferret hearts.

Authors:  M Kitakaze; H F Weisman; E Marban
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

8.  Ischemia and reperfusion increase 125I-labeled endothelin-1 binding in rat cardiac membranes.

Authors:  J Liu; R Chen; D J Casley; W G Nayler
Journal:  Am J Physiol       Date:  1990-03

9.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

10.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03
View more
  2 in total

Review 1.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

2.  Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits.

Authors:  M R Soma; E Donetti; R Seregni; L Barberi; R Fumagalli; R Paoletti; A L Catapano
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.